Peter J Mullen

Title(s)Assistant Professor of Molecular Microbiology and Immunology
SchoolKeck School of Medicine of Usc
Address1501 San Pablo St.
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Peter J. Mullen, Ph.D., is an Assistant Professor of Microbiology and Immunology in the Keck School of Medicine at the University of Southern California (USC). He has a secondary appointment in the Leonard Davis School of Gerontology at USC.
    He has spent over 10 years studying the regulation and role of metabolism in tumor growth and viral infections. The overall goal of his recently established lab is to understand how whole-body metabolism alters respiratory virus replication, cancer progression and aging. By elucidating specific requirements for different nutrients, he aims to identify and develop novel strategies that reduce disease and increase lifespan.

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Nat Cancer. 2022 11; 3(11):1386-1403. Halbrook CJ, Thurston G, Boyer S, Anaraki C, Jiménez JA, McCarthy A, Steele NG, Kerk SA, Hong HS, Lin L, Law FV, Felton C, Scipioni L, Sajjakulnukit P, Andren A, Beutel AK, Singh R, Nelson BS, Van Den Bergh F, Krall AS, Mullen PJ, Zhang L, Batra S, Morton JP, Stanger BZ, Christofk HR, Digman MA, Beard DA, Viale A, Zhang J, Crawford HC, Pasca di Magliano M, Jorgensen C, Lyssiotis CA. PMID: 36411320; PMCID: PMC9701142.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    2. Methionine restriction forces Epstein-Barr virus out of latency. Cell Metab. 2022 09 06; 34(9):1229-1231. Kashyap SB, Mulondo R, Mullen PJ. PMID: 36070678.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. The Metabolic Relationship Between Viral Infection and Cancer. Annual Review of Cancer Biology. 2022; 6:1-15. Peter J Mullen and Heather R Christofk. . View Publication.
    4. SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. Nat Commun. 2021 03 25; 12(1):1876. Mullen PJ, Garcia G, Purkayastha A, Matulionis N, Schmid EW, Momcilovic M, Sen C, Langerman J, Ramaiah A, Shackelford DB, Damoiseaux R, French SW, Plath K, Gomperts BN, Arumugaswami V, Christofk HR. PMID: 33767183; PMCID: PMC7994801.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    5. Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth. Cell Metab. 2021 05 04; 33(5):1013-1026.e6. Krall AS, Mullen PJ, Surjono F, Momcilovic M, Schmid EW, Halbrook CJ, Thambundit A, Mittelman SD, Lyssiotis CA, Shackelford DB, Knott SRV, Christofk HR. PMID: 33609439; PMCID: PMC8102379.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    6. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer Prostatic Dis. 2020 12; 23(4):630-637. Longo J, Hamilton RJ, Masoomian M, Khurram N, Branchard E, Mullen PJ, Elbaz M, Hersey K, Chadwick D, Ghai S, Andrews DW, Chen EX, van der Kwast TH, Fleshner NE, Penn LZ. PMID: 32203069; PMCID: PMC7655503.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    7. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Mol Metab. 2019 07; 25:119-130. Longo J, Mullen PJ, Yu R, van Leeuwen JE, Masoomian M, Woon DTS, Wang Y, Chen EX, Hamilton RJ, Sweet JM, van der Kwast TH, Fleshner NE, Penn LZ. PMID: 31023626; PMCID: PMC6600047.
      View in: PubMed   Mentions: 31     Fields:    Translation:AnimalsCells
    8. MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. Cancer Cell. 2018 10 08; 34(4):579-595.e8. Tu WB, Shiah YJ, Lourenco C, Mullen PJ, Dingar D, Redel C, Tamachi A, Ba-Alawi W, Aman A, Al-Awar R, Cescon DW, Haibe-Kains B, Arrowsmith CH, Raught B, Boutros PC, Penn LZ. PMID: 30300580.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimalsCells
    9. Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP Destabilization. Cell. 2018 09 20; 175(1):117-132.e21. Sullivan WJ, Mullen PJ, Schmid EW, Flores A, Momcilovic M, Sharpley MS, Jelinek D, Whiteley AE, Maxwell MB, Wilde BR, Banerjee U, Coller HA, Shackelford DB, Braas D, Ayer DE, de Aguiar Vallim TQ, Lowry WE, Christofk HR. PMID: 30197082; PMCID: PMC6151140.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    10. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins. Cancer Res. 2018 03 01; 78(5):1347-1357. Yu R, Longo J, van Leeuwen JE, Mullen PJ, Ba-Alawi W, Haibe-Kains B, Penn LZ. PMID: 29229608.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    11. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget. 2017 Jun 27; 8(26):42857-42875. Meehan J, Ward C, Turnbull A, Bukowski-Wills J, Finch AJ, Jarman EJ, Xintaropoulou C, Martinez-Perez C, Gray M, Pearson M, Mullen P, Supuran CT, Carta F, Harrison DJ, Kunkler IH, Langdon SP. PMID: 28476026; PMCID: PMC5522111.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    12. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016 11; 16(11):718-731. Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. PMID: 27562463.
      View in: PubMed   Mentions: 248     Fields:    Translation:HumansCells
    13. Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models. Br J Cancer. 2016 Apr 12; 114(8):905-16. Martínez-Pérez C, Ward C, Turnbull AK, Mullen P, Cook G, Meehan J, Jarman EJ, Thomson PI, Campbell CJ, McPhail D, Harrison DJ, Langdon SP. PMID: 27031849; PMCID: PMC4984802.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    14. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. Oncotarget. 2016 Jan 26; 7(4):4695-711. Huang R, Langdon SP, Tse M, Mullen P, Um IH, Faratian D, Harrison DJ. PMID: 26683361; PMCID: PMC4826236.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    15. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget. 2015 Sep 29; 6(29):26909-21. Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, Gebbia M, Lang KS, Giaever G, Nislow C, Moffat J, Penn LZ. PMID: 26353928; PMCID: PMC4694962.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    16. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget. 2015 Sep 22; 6(28):24856-70. Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum JY, Lambin P, Dubois L, Pavathaneni NK, Jarman EJ, Renshaw L, Um IH, Kay C, Harrison DJ, Kunkler IH, Langdon SP. PMID: 26259239; PMCID: PMC4694798.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    17. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood. 2015 Mar 26; 125(13):2120-30. Sriskanthadevan S, Jeyaraju DV, Chung TE, Prabha S, Xu W, Skrtic M, Jhas B, Hurren R, Gronda M, Wang X, Jitkova Y, Sukhai MA, Lin FH, Maclean N, Laister R, Goard CA, Mullen PJ, Xie S, Penn LZ, Rogers IM, Dick JE, Minden MD, Schimmer AD. PMID: 25631767; PMCID: PMC4375109.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCells
    18. Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo. Arch Toxicol. 2016 Jan; 90(1):203-15. Bonifacio A, Mullen PJ, Mityko IS, Navegantes LC, Bouitbir J, Krähenbühl S. PMID: 25300705.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    19. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. Cancer Res. 2014 Sep 01; 74(17):4772-82. Pandyra A, Mullen PJ, Kalkat M, Yu R, Pong JT, Li Z, Trudel S, Lang KS, Minden MD, Schimmer AD, Penn LZ. PMID: 24994712.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    20. Largen: a molecular regulator of mammalian cell size control. Mol Cell. 2014 Mar 20; 53(6):904-15. Yamamoto K, Gandin V, Sasaki M, McCracken S, Li W, Silvester JL, Elia AJ, Wang F, Wakutani Y, Alexandrova R, Oo YD, Mullen PJ, Inoue S, Itsumi M, Lapin V, Haight J, Wakeham A, Shahinian A, Ikura M, Topisirovic I, Sonenberg N, Mak TW. PMID: 24656129.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    21. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Res Treat. 2014 Jan; 143(2):301-12. Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW, Sendorek DH, Haider S, Lehner R, Boutros PC, Penn LZ. PMID: 24337703.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    22. MYC phosphorylation at novel regulatory regions suppresses transforming activity. Cancer Res. 2013 Nov 01; 73(21):6504-15. Wasylishen AR, Chan-Seng-Yue M, Bros C, Dingar D, Tu WB, Kalkat M, Chan PK, Mullen PJ, Huang L, Meyer N, Raught B, Boutros PC, Penn LZ. PMID: 24030976.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    23. Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans. Ther Drug Monit. 2012 Aug; 34(4):406-14. Morand R, Todesco L, Donzelli M, Fischer-Barnicol D, Mullen PJ, Krähenbühl S. PMID: 22743351.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    24. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. Eur J Pharm Sci. 2012 Jul 16; 46(4):244-58. Lebedeva G, Sorokin A, Faratian D, Mullen P, Goltsov A, Langdon SP, Harrison DJ, Goryanin I. PMID: 22085636; PMCID: PMC3398788.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    25. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim Biophys Acta. 2011 Dec; 1813(12):2079-87. Mullen PJ, Zahno A, Lindinger P, Maseneni S, Felser A, Krähenbühl S, Brecht K. PMID: 21839782.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    26. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res. 2011 Jul 01; 17(13):4451-61. Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP. PMID: 21571868.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    27. Matrix metalloproteinases 2 and 9 in the cochlea: expression and activity after aminoglycoside exposition. Neuroscience. 2011 May 05; 181:28-39. Setz C, Brand Y, Radojevic V, Hanusek C, Mullen PJ, Levano S, Listyo A, Bodmer D. PMID: 21354273.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    28. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res. 2010 Nov 15; 70(22):9391-401. Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ. PMID: 20861192.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    29. Pertuzumab for the treatment of ovarian cancer. Expert Opin Biol Ther. 2010 Jul; 10(7):1113-20. Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ. PMID: 20465533.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    30. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol. 2010 Apr 15; 79(8):1200-9. Mullen PJ, Lüscher B, Scharnagl H, Krähenbühl S, Brecht K. PMID: 20018177.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    31. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009 Aug 15; 69(16):6713-20. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, Kay C, Um IH, Langdon S, Goryanin I, Harrison DJ. PMID: 19638581.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    32. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res. 2008 Aug 01; 68(15):6331-40. Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F, Harrison D, Langdon S, Millar RP. PMID: 18676858.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    33. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer. Int J Cancer. 2006 Mar 15; 118(6):1565-71. Mullen P, McPhillips F, Monia BP, Smyth JF, Langdon SP. PMID: 16184551.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    34. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 2005 Aug 01; 65(15):6789-800. Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP. PMID: 16061661.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Peter's Networks
    Concepts (282)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (15)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-1-g3264e86e on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.